Clinical and cost effectiveness of epoprostenol, iloprost, bosentan, sitaxentan, and sildenafil for the treatment of pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation

Chen Y-F, Jowett S, Barton P, Malottki K, Hyde C, Gibbs JSR, Pepke-Zaba J, Fry-Smith A, Roberts J, Moore D
Record ID 32007000343
English
Authors' recommendations: Study found that epoprostenol, iloprost, bosentan, sitaxentan and sildenafil, when added to supportive treatment and used at licensed dose(s), were more effective than supportive treatment alone for the treatment of adults with pulmonary arterial hypertension. The cost-effectiveness of drugs used to treat functional class III patients depends partly on the treatment available in functional class IV and its costs. The only drug currently licensed for functional class IV (epoprostenol) may not be cost-effective by currently used thresholds
Details
Project Status: Completed
URL for project: http://www.hta.ac.uk/1621
Year Published: 2009
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Cost-Benefit Analysis
  • Endothelin Receptor Antagonists
  • Sildenafil Citrate
  • United States
  • Antihypertensive Agents
  • Epoprostenol
  • Hypertension, Pulmonary
  • Iloprost
  • Isoxazoles
  • Phosphodiesterase Inhibitors
  • Piperazines
  • Purines
  • Sulfonamides
  • Sulfones
  • Thiophenes
  • Vasodilator Agents
Contact
Organisation Name: NIHR Health Technology Assessment programme
Contact Address: NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name: journals.library@nihr.ac.uk
Contact Email: journals.library@nihr.ac.uk
Copyright: 2009 Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.